Imagine dealing with plaque psoriasis, a condition that can leave your skin red, itchy, and covered in patches. It affects many people and can be tough to treat, often leading to frustration and discomfort. A new study explored sliding cupping therapy, a traditional Chinese medicine technique, as a potential alternative to narrowband ultraviolet light therapy, a common treatment. Over eight weeks, patients received either cupping or light therapy, and both groups experienced significant improvements in their skin condition. In fact, about 70% of patients in both groups reported positive changes. This means that for those who may not respond well to traditional treatments or prefer alternative options, sliding cupping therapy could be a viable choice. However, while the results are promising, it's important to remember that not every treatment works for everyone. Patients should discuss all available options with their healthcare providers to find the best approach for their needs.
Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 WeeksCould Sliding Cupping Therapy Be a Game-Changer for Psoriasis Patients?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider sliding cupping as an alternative to NBUVB for plaque psoriasis with similar efficacy.
This randomized controlled trial evaluated the efficacy of sliding cupping therapy compared to narrowband ultraviolet B (NBUVB) therapy in 60 patients with plaque psoriasis. Participants were randomized to receive either sliding cupping or NBUVB treatment three times per week for eight weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8. Results showed a mean percentage reduction in PASI of 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between the groups (P=.526). Secondary endpoints, including Physician's Global Assessment (PGA), body surface area, and quality of life measures, also showed no significant differences between the groups at weeks 0, 4, 8, and 12. The total response rates were 69.23% for sliding cupping and 79.17% for NBUVB, which was not statistically significant (P=.526). Safety profiles were similar between the two treatments, with no significant adverse events reported. These findings suggest that sliding cupping therapy may be a viable alternative to NBUVB for managing plaque psoriasis, offering similar efficacy and safety.
What this means for you:
Sliding cupping therapy offers hope for psoriasis patients seeking effective treatment alternatives. More on Psoriasis
Staphylococcal infections may mimic paradoxical psoriasis in patients receiving TNF-alpha inhibitors for systemic conditions
Skin infections can mimic psoriasis during certain medical treatments
This case report series describes 6 patients treated with TNF-alpha antagonists who developed skin lesions initially misdiagnosed as paradox…
Some patients treated for skin conditions may actually have a bacterial infection that looks like a flare-up of their original condition.
Smoking and alcohol linked to higher psoriasis risk in large meta-analysis
Smoking raises psoriasis risk significantly while alcohol shows a smaller effect
This systematic review and meta-analysis of observational studies involving more than 25 million participants found that smoking (RR 1.67) a…
Smoking increases the chance of developing psoriasis, and even quitting keeps that risk higher than never smoking. Alcohol also plays a role…
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…
View Original Abstract ↓
BACKGROUND: The sliding cupping therapy represents a traditional Chinese medicine therapy and receives much appreciation for treating plaque psoriasis. This study was designed to test the hypothesis that sliding cupping therapy is non-inferior to narrowband ultraviolet B (NBUVB) therapy in improving disease severity in patients with plaque psoriasis.
METHODS: This prospective study recruited 60 patients with plaque psoriasis who were randomized to receive either sliding cupping intervention or NBUVB treatment. The cup was moved 30 times for each skin lesion until the target skin area turned purple. The initial dose (mJ/cm2) of ultraviolet radiation b (UVB) was determined based on sun-reactive skin types I through VI, which ranged from 300 mJ/cm2 to 800 mJ/cm2. Both treatments were performed 3 times per week for 8 weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8, with secondary endpoints, including Physician's Global Assessment (PGA), body surface area, visual analogue scale scores, and quality of life measures.
RESULTS: The total response rates were 69.23% (18/26) and 79.17% (19/24) for patients receiving sliding cupping intervention and those receiving NBUVB treatment, respectively, which showed no significant difference (P = .526). The PASI scores, body surface area, and PGA were reduced in patients with plaque psoriasis at W0, W4 and W8 after either sliding cupping intervention or NBUVB treatment (P <.001), and these reductions were not significantly different between the patients receiving sliding cupping intervention and those receiving NBUVB treatment at W0, W4, W8, and W12. At W8, the mean percentage reduction in PASI was 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between groups. The total response rates were 69.23% (18/26) and 79.17% (19/24), respectively (P = .526). Patients receiving sliding cupping intervention and those receiving NBUVB treatment did not show statistically significant differences in these outcomes at W0, W4, W8, and W12 (P >.05).
CONCLUSION: The overall results suggest that sliding cupping therapy exhibits statistically similar efficacy and safety profiles as NBUVB treatment, especially at 8 weeks after treatment.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
Nurses share how trauma care shapes their daily work and personal lives
Fifteen experienced trauma nurses shared their lived experiences managing critical multiple injuries in a tertiary Hunan hospital. Their nar…
Fifteen experienced nurses describe the professional challenges, teamwork dynamics, and stress they face while managing critical trauma case…
FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
FDA approves Tremfya for ulcerative colitis and Crohn's disease.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis and Crohn's disease. The approval exp…
The FDA approved Tremfya (guselkumab) for adults with moderate to severe ulcerative colitis or Crohn's disease. It is the first drug of its …
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.